Thromb Haemost 2000; 84(01): 83-87
DOI: 10.1055/s-0037-1613972
Commentary
Schattauer GmbH

Fibrinogen, Fibrin and Crosslinking in Aging Arterial Thrombi

Robert D. McBane II
1   From the Department of Medicine, Division of Cardiovascular Diseases, Rochester, MN, USA
2   Department of Medicine, Section of Hematology Research, Rochester, MN, USA
,
Monique A. P. Ford*
2   Department of Medicine, Section of Hematology Research, Rochester, MN, USA
3   Department of Biochemistry and Molecular Biology, Mayo Clinic and Foundation for Education and Research, Rochester, MN, USA
,
Krzysztof Karnicki
2   Department of Medicine, Section of Hematology Research, Rochester, MN, USA
,
MaryLou Stewart
2   Department of Medicine, Section of Hematology Research, Rochester, MN, USA
,
Whyte G. Owen
2   Department of Medicine, Section of Hematology Research, Rochester, MN, USA
3   Department of Biochemistry and Molecular Biology, Mayo Clinic and Foundation for Education and Research, Rochester, MN, USA
› Author Affiliations
Further Information

Publication History

Received 27 July 1999

Accepted after resubmission 21 February 2000

Publication Date:
10 December 2017 (online)

Summary

The assumption that fibrin and crosslinked fibrin impart irreversibility to arterial thrombi is explored with procedure developed for measuring changes in platelet function, morphology and fibrinogen metabolism in aging occlusive thrombi, in which the condition of stasis is imposed uniformly. Arterial thrombi containing autologous 111In labeled platelets were generated in vivo by bilateral mechanical injury of porcine carotid arteries. Vessels containing the platelet-rich thrombi were harvested and incubated intact (37° C) for intervals ranging from 30 min to 12 h. The isolated vessels were then bisected and agitated in culture medium containing tick anticoagulant and hirudin for 60 min. Disaggregated platelets were evaluated for yield (from 111In radioactivity) viability (dense body ATP secretion) and morphology (electron microscopy). Western analysis of fibrin(ogen) in thrombus extracts was performed using anti-fibrinogen Bβ- and γ-chain monoclonal antibodies for thrombi at each time point. A stable recovery of nearly 50% of platelets was observed during 12 h of thrombus aging. As thrombi aged, viability of disaggregated platelets gradually decreased with platelet necrosis the predominant feature beyond 6 h. By western analysis of thrombus extracts, nearly 50% of fibrinogen was cleaved to fibrin and extensively crosslinked within 30 min of injury with no evidence of fibrinolysis. With the exception of a declining proportion of γ-monomer, these features remain relatively constant during 12 h of thrombus maturation. It is concluded that neither fibrin nor crosslinked fibrin are dominant factors imparting cohesion within platelet thrombi. Furthermore, under conditions of complete arterial occlusion imposed by this experimental design, there is no evidence of endogenous fibrinolysis.

* Current address: University of The West Indies, Mona, Kingston, Jamaica


 
  • References

  • 1 Jorgenson L, Rousell HC, Torstein H, Mustard JF. Resolution and organization of platelet-rich thrombi in carotid arteries of swine. Am J Path 1967; 51: 681-719.
  • 2 Falk E. Dynamics in thrombus formation. Ann NY Acad Sci 1992; 6Z67: 204-23.
  • 3 Wysokinski W, McBane R, Chesebro JH, Owen WG. Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries. Thromb Haemost 1996; 76: 1108-13.
  • 4 Owen WG, Bichler J, Ericson D, Wysokinski W. Gating of thrombin in platelet aggregates by pO2-linked lowering of extracellular Ca2+ concentration. Biochemistry 1995; 34: 9277-81.
  • 5 Reimers HJ, Packham MA, Kinlough-Rathbone RL, Mustard JF. Effect of repeated treatment of rabbit platelets with low concentrations of thrombin on their function, metabolism and survival. Br J Haem 1973; 25: 675-89.
  • 6 Kinlough-Rathbone RL, Mustard JF, Perry DW, Dejana E, Cazenave JP, Packham MA, Harfenist EJ. Factors influencing the deaggregation of human and rabbit platelets. Thromb Haemost 1983; 49: 162-7.
  • 7 Kinlough-Rathbone RL, Perry DW, Packham MA, Mustard JF. Deaggregation of human platelets aggregated by thrombin. Thromb Haemost 1985; 53: 42-4.
  • 8 Kinlough-Rathbone RL, Packham MA, Perry DW, Mustard JF, Cattaneo M. Lack of stability of aggregates after thrombin-induced reaggregation of thrombin-degranulated platelets. Thromb Haemost 1992; 67: 453-7.
  • 9 Peerschke EI. Irreversible platelet fibrinogen interactions occur independently of fibrinogen alpha chain degradation and are not mediated by intact platelet membrane glycoprotein IIb-IIIa complexes. J Lab Clin Med 1988; 111: 84-92.
  • 10 Peerschke EI, Wainer JA. Examination of irreversible platelet-fibrinogen interactions. Am J Physiol 1985; 248: C466-72.
  • 11 Kinlough-Rathbone RL, Perry DW, Guccione MA, Rand ML, Packham MA. Degranulation of human platelets by the thrombin receptor peptide SFLLRN: comparison with degranulation by thrombin. Thromb Haemost 1993; 70: 1019-23.
  • 12 Kinlough-Rathbone RL, Packham MA, Guccione MA, Richardson M, Harfenist EJ, Mustard JF. Characteristics of thrombin-degranulated human platelets: development of a method that does not use proteolytic enzymes for deaggregation. Thromb Haemost 1991; 65: 403-10.
  • 13 Wallis RB. The effect of recombinant hirudin on arterial thrombosis. Adv Exp Med Biol 1993; 340: 237-41.
  • 14 Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-6.
  • 15 McBane RD, Wysokinski WE, Chesebro JH, Owen WG. Antithrombotic action of endogenous porcine protein C activated with a latent porcine thrombin preparation. Thromb Haemost 1995; 74: 879-85.
  • 16 Dewanjee MK, Rao SA, Didisheim P. Indium-111 tropolone, a new highaffinity platelet label: preparation and evaluation of labeling parameters. J Nucl Med 1981; 22: 981-7.
  • 17 Gerrard JM, Phillips D, Rao G, Plow E, Walz D, Ross RHarker, White J. Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules. J Clin Invest 1980; 66: 102-9.
  • 18 Handagama P, Rappolee DA, Werb Z, Levin J, Bainton DF. Platelet alphagranule fibrinogen, albumin, and immunoglobulin G are not synthesized by rat and mouse megakaryocytes. J Clin Invest 1990; 86: 1364-8.
  • 19 Harfenist EJ, Packham MA, Mustard JF. Reversibility of the association of fibrinogen with rabbit platelets exposed to ADP. Blood 1980; 56: 189-98.
  • 20 Reimers HJ, Kinlough-Rathbone RL, Cazenave JP, Senyi AF, Hirsh J, Packham MA, Mustard JF. in vitro and in vivo functions of thrombintreated platelets. Thromb Haemost 1976; 35: 151-66.
  • 21 van Willigen G, Akkerman JW. Protein kinase C and cyclic AMP regulate reversible exposure of binding sites for fibrinogen on the glycoprotein IIB-IIIA complex of human platelets. Biochem J 1991; 273: 115-20.
  • 22 Smyth SS, Joneckis CC. Parise LV. Regulation of vascular integrins. Blood 1993; 81: 2827-43.
  • 23 Fay WP, Murphy JG, Owen WG. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi. Arterioscler Thrombos Vasc Biol 1996; 16: 1277-84.